| 摘要 |
PURPOSE:To provide the titled agent containing a novel compound obtained by bonding an antitumor substance to human immunoglobulin as an active component, capable of transferring the drug efficiently to the tumor site, remaining in the site for a long period to exhibit antitumor effect, and having low cytotoxicity. CONSTITUTION:The objective antitumor agent contains a novel compound obtained by bonding a human immunoglobulin [e.g. F(ab')2] with an antitumor substance (e.g. an alkylation agent such as chlorambucil, an antimetabolic agent such as cytarabine or an antibiotic substance such as mitomycin C), as an active component. The antitumor agent bonded with human immunoglobulin transfers the active drug to the tumor site when administered to the body affected with cancer, and remains at the site for a long period compared with the other organs, and accordingly, it exhibits the antitumor activity in high efficiency. The above compound has extremely low toxicity, can be administered frequently, and is effective to various human cancers (e.g. acute leukemia, malignant lymphoma, melanoma, etc.). It can be administered orally as well as parenterally. Dose: 0.1-10g/day for adult.
|
